HomeEXECUTIVESKevin Hykes Is Appointed President and CEO of Bardy Diagnostics Effective August 31, 2020

Kevin Hykes Is Appointed President and CEO of Bardy Diagnostics Effective August 31, 2020

September 8, 2020

Kevin Hykes has been appointed President and Chief Executive Officer of Bardy Diagnostics, effective August 31, 2020.

Kevin Hykes will also become a member of BardyDx’s Board of Directors. With over 28 years of experience in the medical device industry, Hykes will be responsible for leading the development and execution of short- and long-term business and financial strategies and managing the overall operations of BardyDx.

Gust H. Bardy, M.D., founder and Chairman of BardyDx, commenting on the appointment said “I’m very excited and pleased to have Kevin join our executive team as President and CEO. I’ve had the privilege of working with Kevin when he was CEO of the last company I founded, Cameron Health, where he led the global commercialization of the subcutaneous implantable cardioverter-defibrillator and ultimately our successful sale to Boston Scientific.  I am looking forward to transitioning into my new role as Chief Medical Officer and Chief Innovation Officer and turning day-to-day management of the company over to Kevin as we continue to experience tremendous growth in the adoption of our CAM® p-wave centric patch as the new standard of care in ambulatory cardiac monitoring devices.”

Prior to joining BardyDx, Hykes held operational roles in numerous venture-backed medical device companies including serving as the President and CEO of Relievant Medical Systems, Metavention, Inc., and Cameron Health. Hykes has also been an Operating Partner at both Revival Healthcare Capital and Versant Ventures and currently serves as an independent director at Veran Medical Systems and Metavention, Inc. Earlier in his career, Hykes spent sixteen years at Medtronic where he held leadership positions in the CRM, Neurostimulation, and Cardiac Surgery business in the United States and Europe.

“It’s an honor to join the outstanding team at Bardy Diagnostics and to build upon the significant momentum that the company has established in the marketplace with its best in class ambulatory ECG monitoring and analysis technology,” said Hykes.  “The demonstrated clinical superiority of Bardy Diagnostics’ p-wave centric technology uniquely positions the company to capitalize on the growing interest in remote patient monitoring for patients with chronic health conditions.”

Warren Watson, a Bardy Diagnostics’ board member, continued “I’ve worked with Kevin Hykes at multiple points over the last 20 years and I’m pleased to welcome him to Bardy Diagnostics.  Kevin’s extensive experience leading venture-backed medical device companies and his successful track record commercializing breakthrough technologies on a global basis will be instrumental in taking the company to the next level in its growth trajectory.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy